Actively Recruiting
Study of AAA817 Compared to Standard Care in Adult Men With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer After 177LuLu-PSMA Therapy
Led by Novartis Pharmaceuticals · Updated on 2026-09-22
443
Participants Needed
93
Research Sites
264 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate treatments for adult men with PSMA-positive metastatic castration-resistant prostate cancer mCRPC who have previously received androgen receptor pathway inhibitors, taxane-based chemotherapy, and progressed on or after 177LuLu-PSMA targeted therapy. The study includes both Phase II and Phase III portions to gather detailed information on dosing and to compare the investigational treatment AAA817 with standard care. Participants will be randomly assigned to receive either AAA817, given in cycles of 8 weeks, or the investigators choice of standard of care treatment. The Phase II part focuses on supporting the dose of AAA817, while the Phase III part compares the efficacy and safety of AAA817 against standard treatments. The study is open-label and conducted internationally across multiple centers. During the study, participants will be monitored for biochemical responses, adverse events, and disease progression through imaging scans and clinical assessments over approximately 24 months. The research team will track survival rates, disease control, patient-reported symptoms, and quality of life. Safety and tolerability of AAA817 will be evaluated from the start of treatment until several weeks after the last dose. Overall, the study spans several years, including follow-up periods to assess long-term outcomes.
CONDITIONS
Brief Title
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here